Barclays PLC Purchases 58,897 Shares of ASP Isotopes Inc. (NASDAQ:ASPI)

Barclays PLC increased its position in ASP Isotopes Inc. (NASDAQ:ASPI) by 438.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,330 shares of the company’s stock after purchasing an additional 58,897 shares during the period. Barclays PLC owned approximately 0.10% of ASP Isotopes worth $201,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ASPI. Bank of New York Mellon Corp bought a new position in ASP Isotopes in the 2nd quarter worth about $381,000. Rhumbline Advisers bought a new position in ASP Isotopes during the 2nd quarter valued at about $116,000. Renaissance Technologies LLC lifted its stake in ASP Isotopes by 5.7% during the 2nd quarter. Renaissance Technologies LLC now owns 171,800 shares of the company’s stock valued at $526,000 after acquiring an additional 9,200 shares during the period. Marshall Wace LLP lifted its stake in ASP Isotopes by 389.6% during the 2nd quarter. Marshall Wace LLP now owns 545,072 shares of the company’s stock valued at $1,668,000 after acquiring an additional 433,734 shares during the period. Finally, Fiera Capital Corp bought a new position in ASP Isotopes during the 3rd quarter valued at about $723,000. Institutional investors own 16.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of ASP Isotopes in a research note on Friday, October 4th. They set a “buy” rating and a $4.50 target price on the stock. Canaccord Genuity Group restated a “buy” rating and set a $4.50 target price on shares of ASP Isotopes in a research note on Friday, October 18th.

ASP Isotopes Price Performance

NASDAQ ASPI opened at $6.40 on Wednesday. ASP Isotopes Inc. has a 52 week low of $1.86 and a 52 week high of $9.33. The firm has a market capitalization of $456.90 million, a P/E ratio of -10.49 and a beta of 3.48. The company has a quick ratio of 7.54, a current ratio of 7.55 and a debt-to-equity ratio of 0.80. The company has a 50-day moving average price of $5.45 and a 200-day moving average price of $4.11.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.